Apogee Therapeutics Shares Surge Following AbbVie's Cash Acquisition Offer
Apogoe Therapeutics' stock surged nearly 47% following a proposed $10.9 billion all-cash acquisition offer from AbbVie, which aims to bolster its immunology pipeline with Apogee’s clinical-stage treatments for inflammatory and immune disorders.
Topics: biotechnology market_reaction mergers_and_acquisitions